Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

bidly with dementia and excessive day time sleepiness. We believe that ITI-002 will be uniquely effective in treating these non-motor complications that are associated with Parkinson's disease."

ABOUT ITI-002

ITI-002 is a unique, orally available, investigational drug being developed for the treatment of motor and non-motor impairments accompanying Parkinson's disease and other neurologic and neuropsychiatric disorders, including schizophrenia and Alzheimer's disease.

ITI-002 potently inhibits the PDE1 enzyme in a competitive manner with sub-nanomolar affinity for this subfamily. This compound is very selective for the PDE1 subfamily relative to other PDE subfamilies. ITI-002 has no significant off target activities at other enzymes, receptor or ion channels.

PDE Type I – PDE enzymes hydrolyze and inactivate cyclic nucleotides (cAMP and cGMP) in the brain.  Eleven classes of PDE enzymes with distinct tissue distributions, cyclic nucleotide selectivity, and regulatory factors are known.  The PDE1 family of enzymes, including PDE1A, PDE1B, and PDE1C isoforms, are calcium/calmodulin-dependent, dual-function (cAMP/cGMP) PDEs that are expressed at high levels in mammalian brain. This enzyme subfamily has little influence on basal nucleotide activity and only becomes active under stimulated conditions.  This "on demand" character distinguishes PDE1 from all other PDE family members. PDE1 is enriched in the striatal medium spiny neurons that lose dopamine input in Parkinson's disease and controls the responsiveness of striatal neurons to dopamine. Intra-Cellular Therapies has shown that orally available, small molecule inhibitors of PDE1 restore dopamine signaling in striatal neurons and potentiate the level of motor correction in Parkinson's disease.

About Parkinson's Disease - Parkinson's disease is a progressive, neurodegenerative disease. The prevalence of Parkinson's disease increases with a
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 Continuing its ... products, earned three prestigious MarCom Awards for outstanding creative ... received a Platinum MarCom Award, the organization’s top honor, ... in St. Louis held in April of this year. ... than 14,000 attendees. Additionally, Nerium was awarded a Gold ...
(Date:11/26/2014)... SoundConnect , an award winning unified communications ... Darren Suders has joined the team as Director of ... partner program through innovative offerings, consistent partner ... brings more than 10-years of channel telecommunication experience to ... from policy development, to partner education and to expansion. ...
(Date:11/26/2014)... MINNEAPOLIS , Nov. 25, 2014 Bio-Techne ... it has appointed Robert Gavin to serve ... of the Protein Platforms Division.  Mr. Gavin will be ... business segment, which includes the ProteinSimple business acquired in ... San Jose, California -based ProteinSimple ...
(Date:11/24/2014)... 2014 Five American winners will ... Maktoum Awards for Medical Sciences", in its 8 th ... Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan Award for ... numerous programs that aim to improve health and promote ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... Advances in biotechnology and life science research coupled with broader range ... culture market. Growth is likely to be fueled by heightened interest ... of industrial biopharmaceuticals. , ... San Jose, CA (PRWEB) ...
... today the,submission of the response to the FDA ... Single Dose Containers). In an,Approvable Letter received on ... respect to chemistry, manufacturing, and controls (CMC)., ... response as a Class 2,resubmission, under which the ...
... Calif., Nov. 5 Telik, Inc.,(Nasdaq: TELK ) ... per share, for,the third quarter ended September 30, 2008, ... per share, for the comparable period in 2007. The,$8.0 ... to,corporate and municipal notes investments with an auction reset ...
Cached Biology Technology:Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts 2Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts 3SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R) 2Telik Announces Financial Results for 2008 Third Quarter 2Telik Announces Financial Results for 2008 Third Quarter 3Telik Announces Financial Results for 2008 Third Quarter 4
(Date:11/3/2014)... 2014 Research and Markets has announced ... Technologies, Markets and Companies" to their offering. ... methods, which have already started to play an important role ... replacing the old fashioned bone marrow transplants. Role of cells ... to become a part of medical practice. Stem ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
(Date:11/2/2014)... month,s issue of Physics World , James Dacey ... "valley of death" to take their innovations from the ... the gruelling challenge facing all start-up companies as they ... physicists because of two main factors: physics-based inventions are ... often turn out to be a lot more complicated ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
... October 15,2012 Curabitur molestie mauris sed dolor ... urna. Duis dictum, purus in condimentum tincidunt, nisl lacus porta ... ipsum dolor sit amet, consectetur adipiscing elit. Mauris est velit, ... ac risus cursus mattis nec ut erat. Donec fringilla dapibus ...
... Oct. 16, 2012 MedNet Solutions, a global life ... systems, and Statistics & Data Corporation (SDC), a specialized ... and data management services to the life sciences industry, ... iMedNet ™ EDC platform ...
... Inc. announced that it has signed an agreement ... offer the Covaris M220 Focused-ultrasonicator system to users ... Compact, cost effective, easy-to-use, and quiet; the M220 ... and Proton™ users. The M220 includes integrated cooling, ...
Cached Biology News:Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 3
Tracker Datamatrix RS-1* reads 96 2D Bar-coded tubes within 20 seconds....
Hybridization cassette for one slide...
Complete cell culture media with cytokines...
Request Info...
Biology Products: